---
title: "Cytokinetics, Incorporated (CYTK.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CYTK.US.md"
symbol: "CYTK.US"
name: "Cytokinetics, Incorporated"
industry: "生物技术"
---

# Cytokinetics, Incorporated (CYTK.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.cytokinetics.com](https://www.cytokinetics.com) |

## Company Profile

Cytokinetics, Incorporated 是一家处于后期阶段的生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为美国潜在的虚弱疾病治疗方案。该公司开发的小分子药物候选者主要旨在影响肌肉功能和收缩性。其药物候选者包括 omecamtiv mecarbil，这是一种新型心脏肌球蛋白激活剂，目前正在对心力衰竭患者进行第三阶段临床试验。它还开发了 CK-089，这是一种快速骨骼肌肌钙蛋白激活剂，目前正在进行第一阶段临床试验；CK-586，这是一种小分子心脏肌球蛋白抑制剂，目前正在进行第二阶段临床试验；以及 aficamten，这是一种新型口服小分子心脏肌球蛋白抑制剂，目前正在进...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: C (0.57)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 66 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2609.26% |  |
| Net Profit YoY | -30.45% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -15.94 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8.31B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 87.21M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 281.08% | A |
| Profit Margin | -862.21% | E |
| Gross Margin | -5025.67% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2609.26% | A |
| Net Profit YoY | -30.45% | D |
| Total Assets YoY | 0.03% | C |
| Net Assets YoY | -3646.12% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -11.60% | D |
| OCF YoY | 2609.26% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.06 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 136.28% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Cytokinetics, Incorporated",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "281.08%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-862.21%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-5025.67%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2609.26%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-30.45%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.03%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3646.12%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-11.60%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "2609.26%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "136.28%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.05 | 460/604 | - | - | - |
| PB | -15.94 | 542/604 | - | - | - |
| PS (TTM) | 95.25 | 253/604 | 236.65 | 93.29 | 83.16 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **20**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 10 | 50% |
| Overweight | 7 | 35% |
| Hold | 3 | 15% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 67.94 |
| Highest Target | 136.00 |
| Lowest Target | 61.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CYTK.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CYTK.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CYTK.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.